Brainomix and Pixyl partner to offer multiple sclerosis treatment

pharmafile | November 28, 2022 | News story | Medical Communications  

In a new partnership, UK-based medical software developer Brainomix will distribute Neuro.MS ‒ French medical imaging company Pixyl’s Software as a Service (SaaS) solution for diagnosis and treatment of patients with multiple sclerosis (MS). This deal will be exclusively in the UK and Ireland, the Nordics and some markets across Eastern Europe.


Neuro.MS uses advanced deep learning technology to provide clinicians with clinically-relevant information for neurological disorders, such as MS. It analyses brain MRI images to identify, quantify and track abnormalities within five minutes, providing access to quantified measures of lesion volume and brain atrophy, along with quantified and classified white matter hyperintensities.


Brainomix co-founder and CEO Michalis Papadakis said: “We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions. We recognised that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions. We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”


e-Stroke is a comprehensive stroke imaging solution, which Neuro.MS will be offered alongside with to Brainomix’s existing customer base.


“Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space,” stated Pixyl co-founder and CEO Senan Doyle.


James Spargo

Related Content

No items found

Latest content